The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy.

In a recent issue of Radiotherapy and Oncology , Lohaus and colleagues reported (http://dx.doi.org/10.1016/j.radonc.2014.11.011) on a subgroup analysis from the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) (1). They reported on 221 patients treated with postoperative radiotherapy with concurrent cisplatin (PORT-C) treated over a 5-year period between 2005 and 2010. They investigate the role of human papilloma virus (HPV) in non-oropharynx head and neck cancer and extend findings from several reports that patients with HNC arising in the oropharynx have significantly improved outcomes if their cancer is associated with HPV.

[1]  P. Harari,et al.  The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy. , 2015, Annals of translational medicine.

[2]  K. Ang,et al.  Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  V. Budach,et al.  HPV in , 2014 .

[4]  P. Lambert,et al.  Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  P. Harari,et al.  p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Sue S Yom,et al.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Ang,et al.  Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Harari,et al.  Is radiation dose reduction the right answer for HPV-positive head and neck cancer? , 2014, Oral oncology.

[9]  Menggang Yu,et al.  Prevalence of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma in the United States Across Time , 2014, Chemical research in toxicology.

[10]  A. Sablina,et al.  p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors. , 2014, Cancer research.

[11]  J. Overgaard,et al.  Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  P. Harari,et al.  Enhanced radiation sensitivity in HPV-positive head and neck cancer. , 2013, Cancer research.

[13]  Annie Bruns,et al.  Radiation‐induced loss of cell surface CD47 enhances immune‐mediated clearance of human papillomavirus‐positive cancer , 2013, International journal of cancer.

[14]  T. Grob,et al.  HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  J. Taube,et al.  Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. , 2013, Cancer research.

[16]  R. Fisher,et al.  Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[18]  Anjali K. Gupta,et al.  Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. , 2009, Archives of otolaryngology--head & neck surgery.

[19]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.